[
  {
    "ts": null,
    "headline": "Biogen Stock: Is Wall Street Bullish or Bearish?",
    "summary": "Despite Biogen's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=b5c8f7e1da0fa1082976ab0995bcef631f42b87d8ebe8859585f7db2408e56ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763387525,
      "headline": "Biogen Stock: Is Wall Street Bullish or Bearish?",
      "id": 137506778,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Despite Biogen's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=b5c8f7e1da0fa1082976ab0995bcef631f42b87d8ebe8859585f7db2408e56ab"
    }
  },
  {
    "ts": null,
    "headline": "Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments",
    "summary": "BEDFORD, Mass., & CAMBRIDGE, Mass., November 17, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB) today announced the publication of final data from the BUTTERFLY study, a prospective, two-year natural history study in people with Dravet syndrome. Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by recurrent",
    "url": "https://finnhub.io/api/news?id=f18ec17a79570e263c01999eda0148cd495f8766b66e903d7beabff569f1a118",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763382600,
      "headline": "Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments",
      "id": 137504360,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "BEDFORD, Mass., & CAMBRIDGE, Mass., November 17, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB) today announced the publication of final data from the BUTTERFLY study, a prospective, two-year natural history study in people with Dravet syndrome. Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by recurrent",
      "url": "https://finnhub.io/api/news?id=f18ec17a79570e263c01999eda0148cd495f8766b66e903d7beabff569f1a118"
    }
  },
  {
    "ts": null,
    "headline": "Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments",
    "summary": "– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development – – Findings underscore the urgent need for new medicines that target the underlying genetic cause of Dravet syndrome to improve long-term outcomes – CAMBRIDGE, Mass. and BEDFORD, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Thera",
    "url": "https://finnhub.io/api/news?id=7d1817a2d179e90b9ff79a1b5397194eb427ee736d923b845d47834fd0d0a40d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763382600,
      "headline": "Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments",
      "id": 137504359,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development – – Findings underscore the urgent need for new medicines that target the underlying genetic cause of Dravet syndrome to improve long-term outcomes – CAMBRIDGE, Mass. and BEDFORD, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Thera",
      "url": "https://finnhub.io/api/news?id=7d1817a2d179e90b9ff79a1b5397194eb427ee736d923b845d47834fd0d0a40d"
    }
  },
  {
    "ts": null,
    "headline": "Biogen acquires Alcyone to boost CNS drug delivery",
    "summary": "ThecaFlex DRx is an implantable device designed to improve treatment options for patients with neurological disorders.",
    "url": "https://finnhub.io/api/news?id=2345181ad5d8dffa6a5ccb086fa1f2610f9c57fa1178df20d8fba97b3b5d6605",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763378936,
      "headline": "Biogen acquires Alcyone to boost CNS drug delivery",
      "id": 137504361,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "ThecaFlex DRx is an implantable device designed to improve treatment options for patients with neurological disorders.",
      "url": "https://finnhub.io/api/news?id=2345181ad5d8dffa6a5ccb086fa1f2610f9c57fa1178df20d8fba97b3b5d6605"
    }
  },
  {
    "ts": null,
    "headline": "High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy",
    "summary": "Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12mg dose regimen1Final European Commission decision expected in January 2026SMA is a rare, genetic, neuromuscular disease that affects individuals of all ages2 CAMBRIDGE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the Committee for Medicinal Products for Human",
    "url": "https://finnhub.io/api/news?id=0b09eb12a8e027b50a7ac551850f5334b691e75dc9814a585d53e80d80578fdf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763377200,
      "headline": "High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy",
      "id": 137504362,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12mg dose regimen1Final European Commission decision expected in January 2026SMA is a rare, genetic, neuromuscular disease that affects individuals of all ages2 CAMBRIDGE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the Committee for Medicinal Products for Human",
      "url": "https://finnhub.io/api/news?id=0b09eb12a8e027b50a7ac551850f5334b691e75dc9814a585d53e80d80578fdf"
    }
  }
]